Graft Versus Host Disease clinical trials at UCLA
6 in progress, 4 open to eligible people
Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
open to eligible people ages 12 years and up
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Los Angeles 5368361, California 5332921 and other locations
Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
open to eligible people ages 18 years and up
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Los Angeles 5368361, California 5332921 and other locations
Reduced Intensity or Nonmyeloablative Conditioning With Orca-T for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
open to eligible people ages 18 years and up
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).
Los Angeles 5368361, California 5332921 and other locations
PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
open to eligible people ages 12 years and up
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
Los Angeles 5368361, California 5332921 and other locations
Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Sorry, accepting new patients by invitation only
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Los Angeles 5368361, California 5332921 and other locations
Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Sorry, in progress, not accepting new patients
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Los Angeles 5368361, California 5332921 and other locations
Last updated: